GlassScriptPhysician profile
Chaz J Moore
NPI 1588334080
$4,059.95
in general payments reported to CMS, 2019-2025
33 companies · $36.97 in 2025
The $36.97 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.91 · 2022: $1,830 · 2023: $1,316 · 2024: $785 · 2025: $36.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,105.65 | 2021-2025 | |
| Novo Nordisk INC | $491.23 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $271.44 | 2021-2024 | Trelegy Ellipta |
| Pfizer INC. | $241.84 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $230.07 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $224.17 | 2022-2024 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $189.05 | 2022-2023 | |
| Lilly USA, LLC | $174.73 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Collegium Pharmaceutical, INC. | $129.63 | 2022-2024 | Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.76 | 2022-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $89.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $86.53 | 2023-2024 | Spravato |
| Daiichi Sankyo INC. | $81.95 | 2022-2023 | Injectafer |
| Exact Sciences Corporation | $79.92 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $72.38 | 2021-2023 | Dificid, Belsomra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $63.67 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.88 | 2022-2023 | Jardiance |
| Amgen INC. | $53.66 | 2022-2023 | Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $43.54 | 2023 | Eliquis |
| Nestle Healthcare Nutrition INC. | $30.93 | 2022 | |
| Madrigal Pharmaceuticals | $26.81 | 2024 | Resmetirom |
| Astellas Pharma US INC | $26.37 | 2023 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.88 | 2024 | Caplyta |
| Kyowa Kirin, INC. | $22.59 | 2023 | |
| Corcept Therapeutics | $21.17 | 2024 | Korlym |
| Medtronic, INC. | $20.56 | 2024 | Intellis Adaptivestim |
| Heartflow, INC. | $20.30 | 2024 | |
| Aimmune Therapeutics, INC. | $19.93 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $19.13 | 2022 | |
| Mylan Specialty L.P. | $13.07 | 2022 | |
| Amarin Pharma, INC. | $12.90 | 2022 | |
| Forte Bio-Pharma LLC | $11.95 | 2021 | |
| Sumitomo Pharma America, INC. | $7.19 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaz Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.